February 16-17, 2027 | Miami Beach
Pioneering Regenerative Macrophage Therapy in Inflammatory and Fibrotic Diseases.
Clinical stage company with lead asset in Ph1/2 in end-stage liver disease, with clinical PoC in compensated cirrhosis.